171 related articles for article (PubMed ID: 36915289)
1. The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity.
Labrousse G; Vande Perre P; Parra G; Jaffrelot M; Leroy L; Chibon F; Escudie F; Selves J; Hoffmann JS; Guimbaud R; Lutzmann M
NAR Cancer; 2023 Jun; 5(2):zcad011. PubMed ID: 36915289
[TBL] [Abstract][Full Text] [Related]
2. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
[TBL] [Abstract][Full Text] [Related]
3. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.
Huang F; Tanaka H; Knudsen BS; Rutgers JK
BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
[TBL] [Abstract][Full Text] [Related]
4. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
5. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.
Shinbrot E; Henninger EE; Weinhold N; Covington KR; Göksenin AY; Schultz N; Chao H; Doddapaneni H; Muzny DM; Gibbs RA; Sander C; Pursell ZF; Wheeler DA
Genome Res; 2014 Nov; 24(11):1740-50. PubMed ID: 25228659
[TBL] [Abstract][Full Text] [Related]
6. Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction.
Hamzaoui N; Alarcon F; Leulliot N; Guimbaud R; Buecher B; Colas C; Corsini C; Nuel G; Terris B; Laurent-Puig P; Chaussade S; Dhooge M; Madru C; Clauser E
Genet Med; 2020 Sep; 22(9):1533-1541. PubMed ID: 32424176
[TBL] [Abstract][Full Text] [Related]
7. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
8. Characterization of hotspot exonuclease domain mutations in the DNA polymerase ϵ gene in endometrial cancer.
Tian W; Ji Z; Wang J; Meng J; Bi R; Ren Y; Shan B; Yang G; Wang H
Front Oncol; 2022; 12():1018034. PubMed ID: 36313640
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P; Viana-Errasti J; García-Mulero S; Magraner-Pardo L; Muñoz IG; Pons T; Capellá G; Pineda M; Feliubadaló L; Valle L
Genome Med; 2023 Oct; 15(1):85. PubMed ID: 37848928
[TBL] [Abstract][Full Text] [Related]
10. Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
Rocque MJ; Leipart V; Kumar Singh A; Mur P; Olsen MF; Engebretsen LF; Martin-Ramos E; Aligué R; Sætrom P; Valle L; Drabløs F; Otterlei M; Sjursen W
Mol Genet Genomics; 2023 May; 298(3):555-566. PubMed ID: 36856825
[TBL] [Abstract][Full Text] [Related]
11. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
Dong S; Zakaria H; Hsiehchen D
Oncologist; 2022 Mar; 27(3):159-162. PubMed ID: 35274726
[TBL] [Abstract][Full Text] [Related]
12. First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene.
Rosa RCA; Yurchenko AA; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Kannouche PL; Nikolaev S; Ferraz VEF
Genet Mol Biol; 2020; 43(4):e20200100. PubMed ID: 33001133
[TBL] [Abstract][Full Text] [Related]
13. Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency.
Sehested A; Meade J; Scheie D; Østrup O; Bertelsen B; Misiakou MA; Sarosiek T; Kessler E; Melchior LC; Munch-Petersen HF; Pai RK; Schmuth M; Gottschling H; Zschocke J; Gallon R; Wimmer K
Hum Mutat; 2022 Jan; 43(1):85-96. PubMed ID: 34816535
[TBL] [Abstract][Full Text] [Related]
14. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
15. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
16. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
17. A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.
Cui J; Chen X; Zhai Q; Chen N; Li X; Zhang Y; Wang H; Bian X; Gao N; Chen D; Chen Z; Zhang S; Chen Y
Diagn Pathol; 2023 Feb; 18(1):19. PubMed ID: 36765365
[TBL] [Abstract][Full Text] [Related]
18. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
[TBL] [Abstract][Full Text] [Related]
19. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
20. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
